- No posts yet.
- Health system reform dominates early weeks, then gives way to biomedical breakthroughs and HIQA regulatory updates; Covid booster uptake concern goes silent 30-day briefing • 2026-05-11 - 2026-06-09
- AI-designed vaccine and ERAP1 inhibitor show early promise; HIQA updates disability standards 7-day briefing • 2026-06-03 - 2026-06-09
- Irish health debate pivots from stalled reform narratives to biomedical innovation, while booster uptake silence raises pandemic readiness concerns. 90-day briefing • 2026-03-12 - 2026-06-09
- Ireland's health debate cycles from stagnant reform to biomedical innovation, while chronic capacity deficits and low vaccine uptake remain unresolved. 365-day briefing • 2025-06-10 - 2026-06-09
- First human trial of AI-designed universal coronavirus vaccine and promising cancer drug results lead medical advances this week 7-day briefing • 2026-05-31 - 2026-06-06
- Ireland unveils Sláintecare 2025+ roadmap and 2026 Waiting List Plan amid HSE briefing revealing systemic staffing and capacity deficits. 7-day briefing • 2026-05-24 - 2026-05-30
- Rapid Review of Rozanolixizumab (Rystiggo) for gMG Completed by NCPE ncpe.ie | 11d ago
- NCPE Rapid Review Recommends Full HTA for Zilucoplan (Zilbrysq) for Generalized Myasthenia Gravis ncpe.ie | 13d ago
- NCPE Recommends Against Reimbursement of Belzutifan (Welireg) for von Hippel-Lindau Disease in Ireland ncpe.ie | 15d ago
- Ireland's health system faces record waiting lists and low booster uptake as new plans draw criticism 7-day briefing • 2026-05-17 - 2026-05-23
- Ireland's health system under sustained pressure with record waiting lists and low vaccine uptake; no material change over the period. 30-day briefing • 2026-04-24 - 2026-05-23
- Ireland's health system stagnation hardens: record waiting lists and low vaccine uptake persist with no structural reform progress. 90-day briefing • 2026-02-23 - 2026-05-23
- Ireland's health system stagnation hardens into a chronic, unresolved crisis with no structural reform or innovation across the year. 365-day briefing • 2025-05-24 - 2026-05-23
- NCPE Ireland HTA for Opdualag (nivolumab+relatlimab) for advanced melanoma: status update ncpe.ie | 18d ago
- Dostarlimab (Jemperli) – NCPE Rapid Review Recommends Full HTA for Endometrial Cancer ncpe.ie | 19d ago
- NCPE Assessment: Belzutifan not cost-effective for VHL disease-associated tumours at current price ncpe.ie | 39d ago
- NCPE Recommends Belzutifan (Welireg) Not Reimbursed for VHL Disease on Cost-Effectiveness Grounds ncpe.ie | 39d ago
- National Centre for Pharmacoeconomics Publishes Budget Impact Guideline Version 1.1 ncpe.ie | 57d ago
- NCPE Publishes Updated Budget Impact Model Template v2.3 for Drug Reimbursement Submissions ncpe.ie | 57d ago
- NCPE Releases Full HTA Submission Template Version 3.1 for Pharmacoeconomic Assessments in Ireland ncpe.ie | 628d ago
Showing page 1 of 2
(21 total results)
← Prev
Next →